SVA (Sinovac Biotech) Change In Receivables: $30.9 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SVA Sinovac Biotech Ltd SVA
12 GF Score
Price $6.47
! 9 Warning Signs
View Full Analysis

What is Sinovac Biotech Change In Receivables?

Sinovac Biotech SVA 12 Change In Receivables is $30.9 Mil as of Jun. 2026. GuruFocus rates SVA with a GF Score™ of 12/100. The stock has 9 warning signs investors should review.

Sinovac Biotech's change in receivables for the quarter that ended in Jun. 2026 was $36.3 Mil. It means Sinovac Biotech's Accounts Receivable declined by $36.3 Mil from Dec. 2025 to Jun. 2026 .

Sinovac Biotech's change in receivables for the fiscal year that ended in Dec. 2025 was $24.3 Mil. It means Sinovac Biotech's Accounts Receivable declined by $24.3 Mil from Dec. 2024 to Dec. 2025 .

Sinovac Biotech's Accounts Receivable for the quarter that ended in Jun. 2026 was $265.9 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Sinovac Biotech's Days Sales Outstanding for the six months ended in Jun. 2026 was 329.94.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Sinovac Biotech's liquidation value for the six months ended in Jun. 2026 was $4,102.1 Mil.

Sinovac Biotech  (NAS:SVA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Sinovac Biotech's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=265.9/147.079*91
=329.94

2. In Ben Graham's calculation of liquidation value, Sinovac Biotech's accounts receivable are only considered to be worth 75% of book value:

Sinovac Biotech's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=5523.214-1673.884+0.75 * 265.9+0.5 * 106.611
=4,102.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinovac Biotech Change In Receivables Related Terms

Sinovac Biotech Change In Receivables Historical Data

* Premium members only.

The historical data trend for Sinovac Biotech's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinovac Biotech Change In Receivables Chart

Sinovac Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -710.36 289.60 41.41 87.73 24.27

Sinovac Biotech Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.37 42.37 29.75 -5.48 36.35
SVA
12GF Score
Sinovac Biotech Ltd SVA
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinovac Biotech Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $30.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $30.9 Mil mean?
Sinovac Biotech (SVA) has a Change In Receivables of $30.9 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Sinovac Biotech and its competitors.
Is Sinovac Biotech's Change In Receivables too high?
Sinovac Biotech's current Change In Receivables is $30.9 Mil. Overall, Sinovac Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sinovac Biotech's Change In Receivables compare to INBX and HLVX?
Sinovac Biotech's Change In Receivables of $30.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Sinovac Biotech and its competitors. Sinovac Biotech's current Change In Receivables is $30.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinovac Biotech stock overvalued right now?
Sinovac Biotech (SVA) has a current Change In Receivables of $30.9 Mil. The current Change In Receivables is $30.9 Mil. Sinovac Biotech's overall GF Score™ is 12/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Sinovac Biotech (SVA), the current Change In Receivables is $30.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sinovac Biotech Business Description

Address No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with unmet medical needs. It has developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus. The Company operates exclusively in the research, development, manufacture, and commercialization of vaccines sector. The Company's business is considered as operating in one segment. It has presence in Chinese Mainland, and Outside Chinese Mainland.
12GF Score

Get the complete analysis for SVA

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.47
Price